The renewal of this research program addresses two critical bottlenecks in Alzheimer's disease (AD) research: earlier detection of those at risk and identification of important biological processes during preclinical and early stages of disease. These challenges are the key to development of diagnostic and therapeutic approaches, as well as prevention strategies that will need to be implemented at least 5-10 years before dementia onset. During the prior funding period, this project contributed novel information on individuals with amnestic mild cognitive impairment (MCI) and helped drive the field toward a focus on pre-MCI stages. A major innovation has been the investigation of euthymic older adults with cognitive complaints that score within the normal range on cognitive testing. In this group we have reported alterations in brain structure, functional activation, and connectivity in a network of memory-related regions that are typically intermediate between the pattern seen in cognitively normal controls (CN) and individuals with MCI. This phenotype, now referred to as subjective cognitive decline (SCD) and defined by an international consensus panel in 2013, is influencing large-scale studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which adopted the Cognitive Change Index (CCI) developed in this project to recruit a similar group (SMC). We piloted a dual- tracer PET approach to study molecular signatures as a function of stage of disease, initially examining the relationship of amyloid burden and immune activation (microglia). With the new availability of PET tracers for in vivo measurement of tau burden, we will measure both tau and amyloid in preclinical and prodromal stages of AD, focusing on targeted regions based on neuropathological studies. The role of amyloid and tau deposition as molecular drivers of early functional disruption of brain activity and connectivity, as well as neurodegeneration, will be investigated using an integrated ensemble of advanced MRI approaches including structural MRI, memory task and resting state fMRI, arterial spin labeled perfusion (3D pCASL), and diffusion imaging (DTI and NODDI) on the Prisma 3T platform with 64 channel RF coil and new multiband acquisition sequences. Banking and analysis of fluid biomarkers (blood, CSF) and analysis of APOE and other candidate genes will provide a biological context and new opportunities to understand very early changes from a systems biology perspective. The overall objectives of this research are to validate early prognostic biomarkers and enhance the understanding of biological mechanisms in early stages through accomplishing three specific aims: (1) Determine the stage-specific profile of functional disruption of brain activity and connectivity, tau and amyloid burden, microvascular pathology, neurodegeneration, and inflammation in preclinical and prodromal AD; (2) Determine the temporal relationships and interactions among pathophysiological domains; and (3) Determine which combination of baseline markers is most predictive of clinical and MRI progression on follow- up. The ultimate impact of this research is to facilitate the development of effective precision medicine for AD.

Public Health Relevance

Alzheimer's disease is a common, complex, very costly and often devastating condition with an increasing prevalence as the population ages. Although the symptoms of Alzheimer's disease typically begin with subtle changes in episodic memory, underlying biological changes may occur over several decades prior to symptom onset. The proposed advanced structural, functional and molecular neuroimaging, biomarker and genetic methods will facilitate better early detection and mechanistic understanding of early disease stages which will be critical for development of effective therapeutic and preventative approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG019771-14
Application #
9966841
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
2001-09-15
Project End
2022-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Swinford, Cecily G; Risacher, Shannon L; Charil, Arnaud et al. (2018) Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition. Alzheimers Dement (Amst) 10:322-331
Yan, Jingwen; Liu, Kefei; Li, Huang et al. (2018) JOINT EXPLORATION AND MINING OF MEMORY-RELEVANT BRAIN ANATOMIC AND CONNECTOMIC PATTERNS VIA A THREE-WAY ASSOCIATION MODEL. Proc IEEE Int Symp Biomed Imaging 2018:6-9
Apostolova, Liana G; Risacher, Shannon L; Duran, Tugce et al. (2018) Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurol 75:328-341
Zigon, Bob; Li, Huang; Yao, Xiaohui et al. (2018) GPU Accelerated Browser for Neuroimaging Genomics. Neuroinformatics 16:393-402
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa et al. (2018) Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement 14:43-53
Tometich, Danielle; Small, Brent J; Carroll, Judith E et al. (2018) Pre-treatment psychoneurological symptoms and their association with longitudinal cognitive function and quality of life in older breast cancer survivors. J Pain Symptom Manage :
Cong, Shan; Risacher, Shannon L; West, John D et al. (2018) Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans. Brain Imaging Behav 12:1583-1595
Miller, Jason E; Shivakumar, Manu K; Risacher, Shannon L et al. (2018) Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. Pac Symp Biocomput 23:365-376
Wang, Xiaoqian; Chen, Hong; Yan, Jingwen et al. (2018) Quantitative trait loci identification for brain endophenotypes via new additive model with random networks. Bioinformatics 34:i866-i874
Risacher, Shannon L; Farlow, Martin R; Bateman, Daniel R et al. (2018) Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET. Acta Neuropathol Commun 6:114

Showing the most recent 10 out of 208 publications